Rybelsus, generically known as Semaglutide Tablets, is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Unlike the traditionally administered injectable diabetes medications, Rybelsus comes in tablet form. This is a game-changing convenience, addressing a major barrier that many patients encounter with injectable therapies. The pill offers a comparatively less intrusive, more manageable treatment regime, thereby increasing patient adherence to medication schedules.